---
title: Tumour mutational burden and survival with molecularly matched therapy
date: '2023-08-06'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37544709/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20230807180848&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'CONCLUSION: A high TMB was associated with unfavourable outcome in patients
  receiving molecularly matched therapy, indicating untargeted resistance pathways.
  Therefore, TMB should be further investigated as a predictive biomarker in precision
  oncology ...'
disable_comments: true
---
CONCLUSION: A high TMB was associated with unfavourable outcome in patients receiving molecularly matched therapy, indicating untargeted resistance pathways. Therefore, TMB should be further investigated as a predictive biomarker in precision oncology ...